Vor Biopharma INC Form 4 insider transactions

A director and 10% owner of Vor Biopharma Inc., Reprogrammed Interchange LLC, sold 41,352 shares of common stock across multiple transactions in early October 2025.

Pre-funded warrants held by RA Capital Management and its affiliates for Vor Biopharma Inc. became exercisable on September 18, 2025, making them reportable under Section 16.

Reprogrammed Interchange LLC, a 10% owner and director, reported the sale of 447,278 shares of Vor Biopharma Inc. common stock for $1.5401 per share.

A 10% owner and director of Vor Biopharma Inc. reported multiple sales of common stock totaling 984,805 shares in mid-September 2025.

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold 1,263,647 shares of common stock in early September 2025.

A director affiliated with RA Capital Management received 60,000 stock options in Vor Biopharma Inc. as part of non-employee compensation.

Vor Biopharma Director Sarah Burgess Reed was granted 60,000 stock options with an exercise price of $1.98, vesting monthly over three years, though she disclaims beneficial ownership.

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma Inc., sold over 1.4 million shares of common stock in early September 2025.

Reprogrammed Interchange LLC, a 10% owner and director, sold over 1.4 million shares of Vor Biopharma Inc. common stock.

Reprogrammed Interchange LLC, a 10% owner and director of Vor Biopharma, sold over 670,000 shares of common stock in late August 2025 under a pre-arranged trading plan.

Vor Biopharma's Chief Development Officer, Qing Che Zuraw, received significant grants of restricted stock units and stock options, aligning executive incentives with long-term company performance.

Vor Biopharma Inc. Director Michel Detheux was granted 60,000 stock options with an exercise price of $2.12, vesting monthly over three years.

Vor Biopharma Inc. Director Alexander Cumbo was granted 60,000 stock options with an exercise price of $2.12, vesting monthly over three years starting August 16, 2025.

Vor Biopharma Inc.'s Chief Financial Officer, Sandesh Mahatme, was granted 13,882,750 restricted stock units, aligning executive incentives with long-term company performance.

Vor Biopharma Inc.'s CEO and Chairman, Jean-Paul Kress, was granted 83.3 million employee stock options with an exercise price of $0.89, vesting over four years.

RA Capital Management and its affiliated funds have reported the grant of 30,000 stock options to director Joshua Resnick in Vor Biopharma Inc. as part of the company's non-employee director compensation policy.

Vor Biopharma Inc. Director Joshua Resnick was granted 30,000 stock options with an exercise price of $0.1868, vesting based on continued service, though he disclaims beneficial ownership as they are held for RA Capital funds.

Vor Biopharma Inc. director Erez Kalir was granted 30,000 stock options with an exercise price of $0.1868 per share, vesting based on continued service.

Vor Biopharma Inc. Director Sven Ante Lundberg was granted 30,000 stock options with an exercise price of $0.1868 as part of the company's non-employee director compensation policy.

Vor Biopharma Inc. director David Charles Lubner was granted 30,000 stock options with an exercise price of $0.1868 as part of the company's non-employee director compensation policy.

Vor Biopharma Inc. director Daniella Beckman was granted 30,000 stock options with an exercise price of $0.1868 per share, vesting over approximately one year.

Matthew R. Patterson, a Director at Vor Biopharma Inc., was granted 30,000 stock options as part of the company's non-employee director compensation policy.

Fouad Namouni, a Director at Vor Biopharma Inc., was granted 30,000 stock options with an exercise price of $0.1868 as part of the company's non-employee director compensation policy.

Robert Ang, CEO of Vor Biopharma Inc., disposed of 2,361 shares of common stock on May 6, 2025, to satisfy tax withholding obligations related to the settlement of restricted stock units.

Tirtha Chakraborty, Chief Scientific Officer & Head of Technical Operations at Vor Biopharma, sold 876 shares of common stock on May 6, 2025, to cover tax obligations related to the settlement of restricted stock units.

Han Wook Choi, CFO of Vor Biopharma Inc., reports a transaction involving common stock related to tax withholding obligations.

Tirtha Chakraborty, Chief Scientific Officer & Head of Technical Operations at Vor Biopharma, reported disposing of shares to cover tax withholding obligations related to the settlement of restricted stock units.

Robert Ang, CEO of Vor Biopharma, reports the disposal of common stock to cover tax obligations related to the settlement of restricted stock units.

Chief Medical Officer Attar Eyal C. of Vor Biopharma Inc. reports selling 2,227 shares of common stock at $1.42 per share on February 13, 2025, under a pre-arranged trading plan.

Eyal C. Attar, Chief Medical Officer of Vor Biopharma Inc., reported selling 2,554 shares of common stock at an average price of $1.37 on February 10, 2025, according to a Form 4 filing.